There is some evidence that patients who participate in clinical trials have improved outcomes compared with patients receiving standard chemotherapy. We look forward if the outcome for patients with stage III and IV non-small cell lung cancer treated on a clinical trial was associated with a better outcome at our institution, a tertiary center in Spain. Patients with NSCLC treated on standard chemotherapy/TKI between 2010 and 2015 were matched with individuals who received 1st line chemotherapy or TKI in a clinical trial in a ratio 2:1. Cases were matched for age (<65 years or >65 years), stage (III or IV), histology (adenocarcinoma, squamous), EGFR status (mutated vs wild-type) and therapy received in 1st line (platinum doublet, TKI). All patients were World Health Organisation (WHO) performance status 0 or 1. Patients in each group were well matched for stage, histological sub type, surgery and treatment. The median follow up for patients treated on a trial was 3.2 years, compared with 2.8 years for matched patients who received standard 1st line therapy. The median overall survival for patients treated on a trial was 19.4 months, compared with 15.8 months for those in a matched control group. The difference between groups was not significant (Log rank test, HR 0.81, 95% CI: 0.42 to 1.35, p=0.5). The difference in overall survival between groups was not significant (Log Rank test, HR 0.87, 95% CI: 0.46 to1.64, p=0.7). Data from our institution, a tertiary center active in clinical trials, shows a good outcome for patients with advanced NSCLC regardless of whether they received 1st line therapy on a clinical trial. There is a trend for a better outcome for those patients that are enrolled in a clinical trial, so this encourages our active participation in clinical research.